The 2020 ASCP Annual Meeting will be held in Miami Beach, Florida from May 26 - 29, 2020. The meeting includes representatives from academia, the National Institutes of Health (NIH), Food and Drug Administration (FDA), European regulatory agencies and industry that will discuss key aspects of neuropsychiatric drug development, including the impact of diagnostic changes and personalized interventions based on biomarkers or genetic information. A Steering Committee chaired by Drs. Susan Kornstein and Mark Rapaport with representation of the sectors that are part of the ASCP community lead the direction of the meeting. Representatives from the FDA, EMA, NIMH, NIDA, NIAAA, the pharmaceutical industry and academia comprise the 2020 Steering Committee. A Program Committee under the leadership of Drs. Erika Saunders and Lee Cohen are responsible for the review of all program submissions.